We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recommendations for Clinical Trial Development in Follicular Lymphoma.
- Authors
Maddocks, Kami; Barr, Paul M.; Cheson, Bruce D.; Little, Richard F.; Baizer, Lawrence; Kahl, Brad S.; Leonard, John P.; Fowler, Nathan; Gordon, Leo I.; Link, Brian K.; Friedberg, Jonathan W.; Ansell, Stephen M.
- Abstract
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.
- Subjects
LYMPHOMA treatment; CLINICAL trials; SURVIVAL analysis (Biometry); HEALTH status indicators; HEALTH outcome assessment; ANTINEOPLASTIC agents; BIOLOGICAL assay; EXPERIMENTAL design; PROGNOSIS; QUALITY of life; TREATMENT effectiveness; PATIENT selection; DISEASE progression
- Publication
JNCI: Journal of the National Cancer Institute, 2017, Vol 109, Issue 3, p1
- ISSN
0027-8874
- Publication type
journal article
- DOI
10.1093/jnci/djw255